We regularly work with healthcare professionals (HCPs) and healthcare organisations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway; health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making.
We want people to know, and understand, what we do and how we do it. We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management.
We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry.
As the primary point of contact with patients, healthcare professionals offer invaluable and expert knowledge on patient outcomes and management of diseases.
Sharing information and best practice on state-of-the-art treatments plays a crucial role in informing the pharmaceutical industry’s efforts to improve patient care, treatment options and patient outcomes.
Prescription medicines developed by the industry are complex products designed to address the needs of patients. The pharmaceutical industry has a special duty to ensure that healthcare professionals are kept constantly in touch with continuing developments in the pharmaceutical field. Indeed, educating healthcare professionals about the medicines and the diseases that they treat benefits patients. Accordingly, meetings and events may be organised between the industry and the professions for the further exchange of ideas and information. In addition, the custom has grown of the industry supporting independent meetings of healthcare professionals intended to update and expand the continuing education of the professions themselves. Many of these meetings could not take place without the support and assistance of the pharmaceutical industry. Companies may legitimately provide assistance that is directly related to the bona fide continuing education of the healthcare professionals and which genuinely facilitates attendance of the healthcare professional for the duration of the educational aspect of the event.
The EFPIA Disclosure Code provides a common basis for reporting across Europe in relation to transfers of value. For more information on this Code visit: http://transparency.efpia.eu or www.ipha.ie
Here in Ireland disclosure of payments made to HCPs and HCOs during 2017, will be available from 30th June 2018.
The publication of this information is made for transparency purposes only, as further detailed in the Pfizer EEA HCP Privacy Notice at https://privacycenter.pfizer.com/en/hcp-ie (section “Disclosures of transfer of value”). It does not entail a general authorisation to those accessing the website to carry out any further processing of health care professionals' (HCP’s) data, such as combining it with the information published on other websites.